 Principia Biopharma NASDAQ: PRNB has recently received a number of price target changes and ratings updates: 4282020 Principia Biopharma was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, Principia Biopharma Inc. is a clinical stage biopharmaceutical company. It offers reversible covalent small molecule drugs ... 